ESC 2012: EHRA achievements EHRA Scientific Documents 2011/2012
|
|
|
- Joshua Ellis
- 5 years ago
- Views:
Transcription
1 WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER ESC 2012: EHRA achievements EHRA Scientific Documents 2011/2012 Prof. Dr. med. Paulus Kirchhof Chair in Cardiovascular Medicine University of Birmingham Centre for Cardiovascular Sciences, Birmingham, UK and Department of Cardiology and Angiology University Hospital Muenster, Germany
2 Financial disclosures Merck Daicchi-Sankyo Pfizer European Union
3 EHRA achievements Atrial fibrillation Sudden death Device therapy Communicating EHRA documents Summary
4 EHRA achievements Atrial fibrillation Sudden death Device therapy Communicating EHRA documents Summary
5 What to ablate in AF ablation? 2 nd AFNET/EHRA consensus document. Kirchhof P, et al. Eur Heart J 30: c. (2009) 2012 AF ablation consensus document. Calkins H, et al. Europace 14: (2012) 2012 ESC AF GL update. Camm AJ, et al. Eur Heart J, published on line 25 August 2012
6 A selective class I indication 2012 AF ablation consensus document. Calkins H, et al. Europace 14: (2012) 2012 ESC AF GL update. Camm AJ, et al. Eur Heart J, published on line 25 August 2012
7 Bleeding risk on anticoagulation EHRA/ WG Thrombosis joint document. Lip GY, et al. Europace 13: (2011)
8 A pathophysiological classification of AF Inheritable AF Monogenic Polygenic Focal AF Complex AF Postoperative AF 3 rd AFNET/EHRA consensus document. Kirchhof P, et al. Europace 14: (2012)
9 EHRA achievements Atrial fibrillation Sudden death Device therapy Communicating EHRA documents Summary
10 Genetic testing for inherited cardiomyopathies Comprehenise description of the clinical relevance and accuracy of genetic testing Follow-up document on management of patients with inherited cardiomoypathies in the making (EHRA 2013) EHRA/HRS consensus statement on genetic testing. Ackerman MJ, et al. Europace 13: (2011)
11 Management of palpitations EHRA position paper on palpitations. Raviele A, et al. Europace 13: (2011)
12 EHRA achievements Atrial fibrillation Sudden death Device therapy Communicating EHRA documents Summary
13 Guidance for lead extraction Overview of the clinical problem Definitions of minimal requirements to perform lead extractions (and training) Clinical guidance Deharo, JC, et al. Europace 14: (2012)
14 Remote monitoring of implanted devices Definitions Devices interrogation: Telemetry to retrieve information Device programming: Bidirectional telemetry Programmer: Receive and transmit info via telemetry Home Monitoring: Remote device able to communicate with CIED Remote Monitoring: Remote wireless communication systems Remote FU: Programmable scheduled transmissions RM: Automatically unscheduled transmissions Pt initiated interrogations: Non-scheduled FU as a result of a patient experiencing a real or perceived clinical event overview of techniques and use overview of reimbursment EHRA/ISNHE joint document. Dubner, S, et al. Europace 14: (2012)
15 EHRA/HRS Expert Consensus Statement on Cardiac Resynchronisation Therapy: Implantation and Follow-up of CRT Devices Six sections 1. Pre-implant evaluation: P Adamson, US, JC Daubert, FR 2. CRT Implantation: J Singh, US 3. Pre-discharge and device programming: C Leclercq, FR 4. Heart failure and device follow-up: C Israel, DE, C Linde, SE, JA Lindenfeld, US 5. Response to CRT: MR Gold, US 6. Special issues: L Saxon, US Claude Daubert, MD, Chair Daubert JC et al Europace published on line 28 Aug 2012
16 5. CRT response: Is there a consensual definition? % Non-responders Claude Daubert, MD, Chair Daubert JC et al Europace published on line 28 Aug 2012
17 EHRA achievements Atrial fibrillation Sudden death Device therapy Communicating EHRA documents Summary
18 Communicating EHRA documents EHRA booklets Slide sets web page apps (soon)
19 EHRA achievements Atrial fibrillation Sudden death Device therapy Communicating EHRA documents Summary
20 EHRA scientific documents often joint documents (ESC and international) standardised procedures for writing and review high visibility of results quality of documents (authors!, reviewers!) publication in Europace derivative products: Booklets, web page, slides, (apps) watch out for more documents at pediatric EP practicalities of NOAC therapy management of inherited cardiomyopathies new devices in heart failure translational approaches to AF use of left atrial appendage occluders
21 EHRA scientific documents The scientific documents committee Paulus Kirchhof (chair) Antonio Raviele (co-chair) Mickael Glikson Bulent Gorenek Josep Brugada Terradellas Jean-Claude Daubert Stephan Willems Ali Oto Irina Savelieva Pedro Adragao Ulrich Schotten EHRA staff (Caroline Demoras, Vanessa Meyen, ) contact EHRA (ehra@escardio.org) or p.kirchhof@bham.ac.uk when you have suggesions for new topics or comments
22 EHRA scientific documents often joint documents (ESC and international) standardised procedures for writing and review high visibility of results quality of documents (authors!, reviewers!) publication in Europace derivative products: Booklets, web page, slides, (apps) watch out for more documents at pediatric EP practicalities of NOAC therapy management of inherited cardiomyopathies new devices in heart failure translational approaches to AF use of left atrial appendage occluders
EHRA Spring Summit Meeting. Welcome address. Angelo Auricchio, MD PhD FESC President of European Heart Rhythm Association
EHRA Spring Summit Meeting Welcome address Angelo Auricchio, MD PhD FESC President of European Heart Rhythm Association EHRA Spring Summit Meeting This Edition News Representatives of 54 ESC-countries
EHRA/EUROPACE 2011 Madrid, Spain June
EHRA/EUROPACE 2011 Madrid, Spain June 26.-29.2011 Implementing modern management in atrial fibrillation patients Proceedings from the 3rd AFNet/EHRA consensus conference EHRA Special Session Different
Comprehensive risk reduction
Comprehensive risk reduction Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options - a report from the 3 rd AFNET/EHRA consensus conference Table
EHRA Position Documents on new technology or standards of care
EHRA Position Documents on new technology or standards of care Prof. Laurent Fauchier Cardiologie, Centre Hospitalier Universitaire Trousseau Tours, France Disclosures Laurent Fauchier: Lecture fees: Bayer,
Criteri di scelta ed appropriatezza prescrittiva dei nuovi anticoagulanti orali
Criteri di scelta ed appropriatezza prescrittiva dei nuovi anticoagulanti orali Elisabetta Toso, MD Città della Salute e della Scienza di Torino Università di Torino THE NEW ANTICOAGULANTS HISTORY Oral
Device detected AF and atrial high rate episodes
Device detected AF and atrial high rate episodes Professor Paulus Kirchhof University of Birmingham Institute of Cardiovascular Sciences SWBH and UHB NHS trusts, Birmingham, UK Department of Cardiovascular
European Heart Rhythm Association launches a practical guide on new oral anticoagulants in atrial fibrillation
European Heart Journal (2013) 34, 791 795 doi:10.1093/eurheartj/eht051 European Heart Rhythm Association launches a practical guide on new oral anticoagulants in atrial fibrillation The European Heart
Introduction. Methods and results
Europace (2015) 1, 468 42 doi:10.1093/europace/euv025 EP WIRE How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the
2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation
European Heart Journal 2012 doi:10.1093/eurheartj/ehs253 ESC 2012 2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation An update of the 2010 ESC Guidelines for the Management
EHRA SUMMIT EHRA ACTIVITIES Prof. Karl-Heinz Kuck, FESC (Germany) EHRA PRESIDENT
EHRA SUMMIT 2015 - EHRA ACTIVITIES 2015 Prof. Karl-Heinz Kuck, FESC (Germany) EHRA PRESIDENT Heart House 26.3.2015 EHRA EHRA is a registered branch of the European Society of Cardiology 1 st sub-specialty
Diagnosing atrial fibrillation using implantable devices
Diagnosing atrial fibrillation using implantable devices Axel Brandes, MD, FESC Associate Professor of Electrophysiology and Cardiac Arrhythmias Dept. of Cardiology, Odense University Hospital, DK HRC
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
EHRA Industry Site Visit. Wednesday 20 September 2017
EHRA 2018 Industry Site Visit Wednesday 20 September 2017 Agenda 10:00 11:00 Presentation of EHRA 2018 Scientific Programme City & Congress Center Building /Expo Lay-out Industry Opportunities 11:00 12:30
Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use?
Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use? Helmut Pürerfellner, MD, Assoc. Prof. Saint Elisabeth s Sisters Hospital Academic Teaching Center Linz/Austria
Acute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT
Acute coronary syndromes A European viewpoint Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT Potential conflicts of interest In the past 2 years Felicita
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
Causal relationship between AF & stroke
7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Causal relationship between AF & stroke Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice,
Should ICD Replacement Be Performed in Octogenarians and/or Severe Comorbidities?
Should ICD Replacement Be Performed in Octogenarians and/or Severe Comorbidities? JC Daubert Rennes, France Disclosure 2008-2011 Medical devices Speaker Consultant Trial committees EBR + + Impulse Dynamics
HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation
HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation
Causal relationship between AF & stroke
7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Causal relationship between AF & stroke Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice,
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Albert L. Waldo, MD, PhD (Hon) The Walter H. Pritchard Professor of Cardiology, Professor of Medicine,and
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:
Cardiac Rhythm Management Coder 2018
Cardiac Rhythm Management Coder 2018 An easy-to-use tool for coding and reimbursement compliance Prepared and Published By: MedLearn Publishing, A Division of MedLearn Media, Inc. 445 Minnesota Street,
The Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert
Albania. Algeria. Armenia. Austria. Belarus. Belgium. Bosnia & Herzegovina. Bulgaria. Croatia. Cyprus. Czech Republic Denmark. Egypt. Estonia. Finland. Former Yugoslav Republic of Macedonia. France. Georgia.
The EHRA White Book 2009 The Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert
Albania. Algeria. Armenia. Austria. Belarus. Belgium. Bosnia & Herzegovina. Bulgaria. Croatia. Cyprus. Czech Republic Denmark. Egypt. Estonia. Finland. Former Yugoslav Republic of Macedonia. France. Georgia.
Remote monotoring of cardiac rhythm devices: present and future Pacemaker and ICD
Remote monotoring of cardiac rhythm devices: present and future Pacemaker and ICD Philippe Mabo University Hospital, Rennes, France ESC congress, Paris 30 August 2011 U642 Disclosures Biotronik: research
Cardiac Rhythm Management Coder 2017
Cardiac Rhythm Management Coder 2017 An easy-to-use tool for coding and reimbursement compliance Prepared and Published By: MedLearn Publishing, A Division of Panacea Healthcare Solutions, Inc. 287 East
ESC Paris Remote monitoring of cardiac rhythm devices: present and future HEART FAILURE
ESC Paris 11-08-30 Remote monitoring of cardiac rhythm devices: present and future HEART FAILURE Frieder Braunschweig MD PhD FESC Associate Professor of Cardiology Karolinska University Hospital Stockholm,
Bi-Ventricular pacing after the most recent studies
Seminars of the Hellenic Working Groups February 18th-20 20,, 2010, Thessaloniki, Greece Bi-Ventricular pacing after the most recent studies Maurizio Lunati MD Director EP Lab & Unit Cardiology Dpt. Niguarda
Make the Connection A clinical compendium on the relationship between AF, stroke, and early intervention
Make the Connection A clinical compendium on the relationship between AF, stroke, and early intervention Data that date back to the 1970 s have illustrated the strong relationship between atrial fibrillation
Continuous ECG telemonitoring with implantable devices: the expected clinical benefits
Continuous ECG telemonitoring with implantable devices: the expected clinical benefits C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany Carsten.Israel@evkb.de Declaration of
Left atrial appendage occlusion
Kardiologie Left atrial appendage occlusion Mischa Kühne Kardiolunch, 10.9.2015 Overall stroke rate 5% per year CHA 2 DS 2 VASC score Most AF patients need protection from stroke ESC guidelines AF, 2010/2012
MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory
MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory DOI: 10.1016/j.tcm.2014.05.012 License: Other (please specify with Rights Statement) Document Version
AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?!
AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?! DRUG#PROPHYLAXIS#OF#AF:# FOCUS#ON#DRONEDARONE# Friday#16C10C2015# Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research
ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES
ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES Isabelle C Van Gelder University Medical Center Groningen The Netherlands ESC stroke council Prague January
Syncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France
Syncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France Syncope in advanced heart failure: high risk of sudden death N = 491 patients with HF (NYHA III-IV)
Introduction. Methods and results
Europace (216) 18, 623 627 doi:1.193/europace/euw9 EP WIRE TheroleoftheArrhythmiaTeam,anintegrated, multidisciplinary approach to treatment of patients with cardiac arrhythmias: results of the European
OHTAC Recommendation: Internet- Based Device-Assisted Remote Monitoring of Cardiovascular Implantable Electronic Devices
OHTAC Recommendation: Internet- Based Device-Assisted Remote Monitoring of Cardiovascular Implantable Electronic Devices Ontario Health Technology Advisory Committee January 2012 Issue Background The Ontario
Department of Medicine III, Martin Luther-University Halle, Germany b. Unità Operativa di Cardiologia, Ospedale Maggiore, Bologna, Italy c
Comparison of CHADS 2 -Score with CHA 2 DS 2 VASc-Score in a prospective multicenter registry on patients with atrial fibrillation undergoing coronary artery stenting -First results from the AFCAS-trial-
Handbook of Oral Anticoagulation Second edition
Handbook of Oral Anticoagulation Second edition Handbook of Oral Anticoagulation Second edition Editors Gregory YH Lip University of Birmingham Birmingham, UK Eduard Shantsila University of Birmingham
OAC after apparently successfull AF ablation: when, why, and how?
Gulf EP Live 2015 - Dubai January 22-24 / 2015 OAC after apparently successfull AF ablation: when, why, and how? Antonio Raviele, MD, FESC, FHRS Past Director Cardiovascular Department, dell Angelo Hospital,
Cryptogenic Stroke: The role of silent Atrial Fibrillation
Cryptogenic Stroke: The role of silent Atrial Fibrillation PD Dr. med. Martin A. Ritter Westfälische Wilhelms-Universität Münster Germany ritterm@uni-muenster.de 1 Turin, 25.10.2014 Agenda 1. What is a
DECLARATION OF CONFLICT OF INTEREST. None to declare
DECLARATION OF CONFLICT OF INTEREST None to declare Influence of left and right ventricular leadtip position on clinical outcome after CRT: results from REVERSE C Thébault 1, C Meunier 1, R Gervais 1,
DOAC support programme. engage supported self-care
DOAC support programme engage supported self-care changes in anticoagulation therapy Managing patients receiving anticoagulation (AC) therapy effectively and consistently can be challenging. Direct oral
Post-ablation Management: Drug therapy, Anticoagulation and long-term Monitoring
Catheter Ablation of Atrial Fibrillation: State of the Art Post-ablation Management: Drug therapy, Anticoagulation and long-term Monitoring Dipen Shah Service de Cardiologie Hospital Cantonal de Genève
Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it?
The 12 International Dead Sea Symposium - Jerusalem March 3-5 /2014 Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it? Antonio Raviele, MD, FESC, FHRS Past Director
Recent observations have focused attention on the PVs as a source of ectopic activity i determining i AF
Atrial Fibrillation in 2010 Panos Vardas Professor of Cardiology President of EHRA Atrial Fibrillation Pathophysiology of AF Triggers Recent observations have focused attention on the PVs as a source of
Interventional solutions for atrial fibrillation in patients with heart failure
Interventional solutions for atrial fibrillation in patients with heart failure Advances in Cardiovascular Arrhythmias Great Innovations in Cardiology Matteo Anselmino, MD PhD Division of Cardiology Department
La strategia diagnostica: il monitoraggio ecg prolungato. Michele Brignole
La strategia diagnostica: il monitoraggio ecg prolungato Michele Brignole ECG monitoring and syncope In-hospital monitoring Holter Monitoring External loop recorder Remote (at home) telemetry Implantable
UTILITY OF THE IMPLANTABLE LOOP RECORDER
UTILITY OF THE IMPLANTABLE LOOP RECORDER John Andriulli, DO Associate Professor of Medicine Director, Arrhythmia Device Program Cooper Medical School of Rowan University Contemporary Practices in Cardiology
Introduction EP WIRE. ... Keywords
Europace (217), 1 6 doi:1.3/europace/eux254 EP WIRE Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association
Left Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017
Left Atrial Appendage Closure Devices Emile Daoud, MD Chief, Cardiac Electrophysiology Wexner Medical Center, The Ohio State University Atrial Fibrillation 1 Adjusted Annual Stroke Risk Using CHA 2 DS
13/09/2018. The ISSUE Studies. International (Italy & Spain) Study of Syncope of Uncertain Etiology. ISSUE study Pre-defined inclusion cathegories
The Studies Jean-Claude Deharo Aix-Marseille Université, France In Cardiac Electrophysiology Methods and Models Editors: Daniel C. Sigg, Paul A. Iaizzo, Yong-Fu Xiao, Bin He Springer 2010 study Pre-defined
SUBCLINICAL ATRIAL FIBRILLATION IN PATIENTS WITH IMPLANTABLE DEVICEs ORAL ANTICOAGULANT THERAPY: TO GIVE OR NOT TO GIVE, THIS IS THE PROBLEM!!
SUBCLINICAL ATRIAL FIBRILLATION IN PATIENTS WITH IMPLANTABLE DEVICEs ORAL ANTICOAGULANT THERAPY: TO GIVE OR NOT TO GIVE, THIS IS THE PROBLEM!! Atrial tachycardia «ATRIAL HIGH RATES EPISODES» (AHREs) Episodes
Novel Anticoagulants: Emerging Evidence
18/10/2016 Topics: Novel Anticoagulants: Emerging Evidence Dr Matthew Swale Electrophysiologist Genesis Care NOAC Novel Oral Anti Coagulant Now Non-Vit K Oral Anti Coagulant DOAC Direct Oral Anti Coagulant
Is QRS width predictive of the clinical and echocardiographic response to chronic CRT in mildly symptomatic HF patients?
Is QRS width predictive of the clinical and echocardiographic response to chronic CRT in mildly symptomatic HF patients? Data from REVERSE C Thébault 1, M Gold 2, C Linde 3, WT Abraham 4, C Leclercq 1,
ESC CONGRESS HIGHLIGHTS ARRHYTHMIAS. M. Bertini (Ferrara, IT) Conflicts of Interest none
ESC CONGRESS HIGHLIGHTS ARRHYTHMIAS M. Bertini (Ferrara, IT) Conflicts of Interest none Data that may change daily practice... Atrial fibrillation OACs in real life - BEYOND program Halvorsen S 2951 OAC
LATITUDE Patient Management System
LATITUDE Patient Management System Boston Scientific Corporation Overview Key Benefits Benefits in HF-Management The future of RPM 2 Boston Scientific Corporation LATITUDE Patient Management Overview Patient
30 Seconds is the Proper Endpoint for AF Ablation YES. Hugh Calkins MD. Professor of Medicine
30 Seconds is the Proper Endpoint for AF Ablation YES Hugh Calkins MD Professor of Medicine Director of Electrophysiology Johns Hopkins Medical Institutions COI Disclosures Dr Calkins is a consultant to
AF Ablation in Patients with Heart Failure
AF Ablation in Patients with Heart Failure Christian de Chillou, MD, PhD Department of Cardiology University Hospital Nancy, France 28ème Journée Internationale du Centre Cardio-Thoracique de Monaco Monaco,
POWERFUL CARDIAC MONITORING
POWERFUL CARDIAC MONITORING Indications, Guidelines, Clinical Evidence, and Coding Overview for Diagnosing Suspected Arrhythmias and Monitoring Known A-Fib Reveal LINQ Insertable Cardiac Monitoring System
STANDARDS FOR INTERVENTIONAL ELECTROPHYSIOLOGY STUDY AND CATHETER ABLATION IN ADULTS January 2014
STANDARDS FOR INTERVENTIONAL ELECTROPHYSIOLOGY STUDY AND CATHETER ABLATION IN ADULTS January 2014 1. INTRODUCTION This document replaces the previous Heart Rhythm UK document Standards for electrophysiological
Review of devices for early AF detection Nadya Hamedi Primary Care cardiovascular pharmacist Health innovation Network
Review of devices for early AF detection Nadya Hamedi Primary Care cardiovascular pharmacist Health innovation Network n.hamedi@nhs.net HRC 2016 The ICC Birmingham UK 9-12 October 2016 PAN London AF Improvement
Atrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
Managing Stroke Prevention in AF: A Closer Look at Non-surgical Interventions
Managing Stroke Prevention in AF: A Closer Look at Non-surgical Interventions Riccardo Cappato, MD Humanitas University Electrophysiology & Arrhythmia Center Humanitas Research Institute, Milan & Gavazzeni
Cardiac resynchronization therapy for heart failure: state of the art
Cardiac resynchronization therapy for heart failure: state of the art Béla Merkely MD, PhD, DSc, FESC, FACC Vice president of the European Society of Cardiology Honorary president of the Hungarian Society
WHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France.
TAVI WITH ATRIAL FIBRILLATION: WHICH ANTITHROMBOTIC REGIMEN? G. MONTALESCOT (PARIS, FR) Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France www.action-cœur.org Dr. Montalescot
ESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
Consensus document: Screening and Prevention of Atrial Fibrillation
Consensus document: Screening and Prevention of Atrial Fibrillation Yong-Seog Oh, M.D.,Ph.D. Division of Cardiology, Department of Internal Medicine, Seoul St. Mary s Hospital, College of Medicine, The
This is What I do to Improve CRT Response for CRT Non-Responders
This is What I do to Improve CRT Response for CRT Non-Responders Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Steering Committees (unpaid) and Clinical Trials,
Severe aortic stenosis should be operated before symptom onset CONTRA. Helmut Baumgartner
Severe aortic stenosis should be operated before symptom onset CONTRA Helmut Baumgartner Westfälische Wilhelms-Universität Münster Adult Congenital and Valvular Heart Disease Center Dept. of Cardiology
EUROPACE 2011 Johan Vijgen, MD, FESC Jessa Hospital Hasselt, Belgium
ICD and Driving: What is Safe? EUROPACE 2011 Johan Vijgen, MD, FESC Jessa Hospital Hasselt, Belgium Background Increasing number of ICD implants, more primary indications, patients are younger and more
Managing Atrial Fibrillation in the Heart Failure Patient
Managing Atrial Fibrillation in the Heart Failure Patient Jonathan S. Steinberg, MD Professor of Medicine (adj) University of Rochester School of Medicine & Dentistry Director, Arrhythmia Institute Valley
Atrial fibrillation (AF) has been the. Subclinical Atrial Fibrillation, Embolic Risk, and Anticoagulant Treatment
MAEDICA a Journal of Clinical Medicine 2018; 13(4): 261-265 https://doi.org/10.26574/maedica.2018.13.4.261 Mædica - a Journal of Clinical Medicine Invited Editorial Point of View Subclinical Atrial Fibrillation,
Left Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
Controversies in Atrial Fibrillation and HF
Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.
Acute Arrhythmias in the Hospitalized Patient
Acute Arrhythmias in the Hospitalized Patient Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisc Disclosures Medtronic: Research Support
Testimony of a failed reimbursement change: why it went wrong Device implantation in Sweden
Testimony of a failed reimbursement change: why it went wrong Device implantation in Sweden Frieder Braunschweig MD PhD FESC FACC Professor of Cardiology, Director of Arrhythmia Heart and Vascular Theme
Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
2018 ESC Guidelines for the diagnosis and management of syncope
2018 ESC Guidelines for the diagnosis and management of syncope Michele Brignole (Chairperson) (Italy); Angel Moya (Co-chairperson) (Spain); Jean-Claude Deharo (France); Frederik de Lange (The Netherlands);
2010 Canadian Cardiovascular Society/ Canadian Heart Rhythm Society Training and Maintenance of Competency in Adult Clinical Cardiac
2010 Canadian Cardiovascular Society/ Canadian Heart Rhythm Society Training and Maintenance of Competency in Adult Clinical Cardiac Electrophysiology Martin S. Green, Chair, CHRS Education Committee Peter
Planning study for minimally invasive cardiac arrhythmias ablation with intensity modulation proton therapy Vennarini Sabina
Planning study for minimally invasive cardiac arrhythmias ablation with intensity modulation proton therapy Vennarini Sabina (sabina.vennarini@apss.tn.it) Introduction Atrial Fibrillation (AF): most common
Preliminary program. 13:15 13:35 Basic steps in electronic device implantations Dr. D. Markov, UMHAT Queen Giovanna Sofia
Preliminary program September 29, Friday 11:00 Registration 13:15 14:00 Teaching module: Allied Professionals Chairs: Dr. N. Bonev, Dr D. Marchov 13:15 13:35 Basic steps in electronic device implantations
Invasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
Why to monitor AF ablation success?
Why to monitor AF ablation success? Why to monitor AF ablation success? CASTLE-AF Primary Endpoint All-cause mortality Worsening heart failure admissions Secondary Endpoints All-cause mortality Worsening
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
North Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease
Guidelines on oral antiplatelet therapy in cardiovascular disease This guidance should be considered as one part of the wider therapeutic management of patients. The indication for antiplatelet therapy
Inappropriate electrical shocks: Tackling the beast
ESC Paris 2011 Inappropriate electrical shocks: Tackling the beast Gerhard Hindricks University of Leipzig Heart Center Dept. of Electrophysiology ESC Paris 2011 Inappropriate electrical shocks: Tackling
Atrial Fibrillation
Atrial Fibrillation 2017-2018 Quality of Life and Preventing Stroke The 14 Clinical Challenges ACC New York, Dec 9, 2017 No Disclosures AF - CLINICAL CHALLENGES (14) 2017-2018 1. Presentation: Simplified
Apixaban versus Heparin/Vitamin K Antagonist in Anticoagulation-naïve Patients with Atrial Fibrillation Scheduled for Cardioversion: The EMANATE Trial
Apixaban versus Heparin/Vitamin K Antagonist in Anticoagulation-naïve Patients with Atrial Fibrillation Scheduled for Cardioversion: The EMANATE Trial Michael D. Ezekowitz, Professor, Sidney Kimmel Medical
TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations
TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations DATE: 29 September 2010 CONTEXT AND POLICY ISSUES: Atrial fibrillation (AF) is the irregular, rapid beating of the
AF detection: What s new? Christopher B. Granger
AF detection: What s new? Christopher B. Granger Disclosures Research contracts: Apple, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Novartis, GSK, Medtronic Foundation, Pfizer,
Unités de syncope : état des lieux en France
Unités de syncope : état des lieux en France sboveda@clinique-pasteur.com 19 Janvier 2018 Paris Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation
Prof. Fiorenzo Gaita
Adavances in Cardiac Arrhythmias and Great Innovations in Cardiology Turin 2014 Can rhythm control strategy reduce the risk of clinical and silent cerebral ischemia? Prof. Fiorenzo Gaita Director of the
Safety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup
Safety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup Martin W. Bergmann, Hüseyin Ince, Stephan Kische, Thomas Schmitz, Felix Meincke, Boris Schmidt, David Foley, Timothy
Sudden death from abnormal heart rhythm: Am I at risk?
DISCLAIMER: The views and opinions expressed in this presentation are those of the author. The slides in this presentation are prepared as talking points. It is possible that key substantive elements were
CADTH Therapeutic Review
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Therapeutic Review August 2012 Volume 1, Issue 1A Antithrombotic Therapy for
Cardiac Event Monitors
Last Review Date: July 14, 2017 Number: MG.MM.DM.18aCv2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
Antithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
Biatrial Maze or PVI to Ablate Afib? Marc Gillinov, MD
Biatrial Maze or PVI to Ablate Afib? Marc Gillinov, MD Disclosures Consultant/Speaker AtriCure Medtronic CryoLife Edwards Abbott Research Funding Abbott Equity Interest Clear Catheter Cleveland Clinic